GlassScriptPhysician profile
Albert P Diloreto
NPI 1417071275
$2,049.29
in general payments reported to CMS, 2019-2025
30 companies · $265 in 2025
The $265 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $166 · 2022: $405 · 2023: $531 · 2024: $682 · 2025: $265.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,478.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,478.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $426.55 | 2022-2025 | Evenity, Prolia, Prolia |
| Depuy Synthes Sales INC. | $243.51 | 2022-2025 | Monovisc, Orthovisc |
| Azurity Pharmaceuticals, INC. | $196.92 | 2024-2025 | Horizant, Edarbi, Edarbyclor |
| Vertos Medical, INC. | $134.93 | 2024 | Mild Device Kit |
| Janssen Biotech, INC. | $134.79 | 2022 | |
| Horizon Therapeutics Plc | $124.24 | 2021 | |
| Medtronic, INC. | $96.07 | 2021-2023 | Intellis Adaptivestim |
| Abbvie INC. | $67.99 | 2023-2024 | |
| Spr Therapeutics, INC | $66.50 | 2024 | Sprint Pns System |
| Vertex Pharmaceuticals Incorporated | $53.54 | 2024-2025 | |
| Collegium Pharmaceutical, INC. | $47.03 | 2023 | Xtampza |
| Idorsia Pharmaceuticals US INC | $36.20 | 2023-2024 | Quviviq |
| Averitas Pharma INC. | $30.76 | 2023 | Qutenza |
| Pfizer INC. | $29.69 | 2021 | |
| Stryker Corporation | $28.23 | 2024 | Mild Device Kit |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Curonix LLC | $26.88 | 2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $26.84 | 2023 | Relistor |
| Ani Pharmaceuticals, INC. | $26.01 | 2025 | Purified Cortrophin Gel |
| Lilly USA, LLC | $25.09 | 2025 | Zepbound, Mounjaro |
| Organon LLC | $24.57 | 2022 | |
| Boston Scientific Corporation | $24.52 | 2022 | |
| Merz Pharmaceuticals, LLC | $24.04 | 2023 | Xeomin |
| Nalu Medical, INC. | $22.46 | 2024 | Nalu Neurostimulation System |
| Pacira Pharmaceuticals Incorporated | $22.36 | 2023 | Iovera, Zilretta |
| Ferring Pharmaceuticals INC. | $22.04 | 2024 | Euflexxa |
| Convatec INC. | $20.49 | 2024 | |
| Mallinckrodt Hospital Products INC. | $19.08 | 2022 | |
| Relievant Medsystems, INC. | $18.25 | 2022 | |
| Novo Nordisk INC | $15.19 | 2024 | Wegovy |
| Sobi, INC | $14.52 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Albert Diloreto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.